- Home
- HRMY vs ATRC Comparison
HRMY vs ATRC Comparison
Compare HRMY & ATRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- ATRC
- Stock Information
- Founded
- HRMY 2017
- ATRC 2000
- Country
- HRMY United States
- ATRC United States
- Employees
- HRMY N/A
- ATRC N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- ATRC Medical/Dental Instruments
- Sector
- HRMY Health Care
- ATRC Health Care
- Exchange
- HRMY Nasdaq
- ATRC Nasdaq
- Market Cap
- HRMY 1.8B
- ATRC 1.6B
- IPO Year
- HRMY 2020
- ATRC 2005
- Fundamental
- Price
- HRMY $34.94
- ATRC $37.54
- Analyst Decision
- HRMY Strong Buy
- ATRC Strong Buy
- Analyst Count
- HRMY 9
- ATRC 10
- Target Price
- HRMY $55.33
- ATRC $49.60
- AVG Volume (30 Days)
- HRMY 627.0K
- ATRC 686.5K
- Earning Date
- HRMY 08-05-2025
- ATRC 07-29-2025
- Dividend Yield
- HRMY N/A
- ATRC N/A
- EPS Growth
- HRMY 58.41
- ATRC N/A
- EPS
- HRMY 3.10
- ATRC N/A
- Revenue
- HRMY $772,527,000.00
- ATRC $499,946,000.00
- Revenue This Year
- HRMY $20.45
- ATRC $14.63
- Revenue Next Year
- HRMY $17.32
- ATRC $12.62
- P/E Ratio
- HRMY $11.29
- ATRC N/A
- Revenue Growth
- HRMY 17.74
- ATRC 16.28
- 52 Week Low
- HRMY $26.47
- ATRC $20.20
- 52 Week High
- HRMY $41.61
- ATRC $43.11
- Technical
- Relative Strength Index (RSI)
- HRMY 50.27
- ATRC 69.41
- Support Level
- HRMY $34.09
- ATRC $33.63
- Resistance Level
- HRMY $36.09
- ATRC $38.11
- Average True Range (ATR)
- HRMY 1.42
- ATRC 1.55
- MACD
- HRMY -0.19
- ATRC 0.78
- Stochastic Oscillator
- HRMY 46.42
- ATRC 93.77
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About ATRC AtriCure Inc.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.